Items where authors include "Yea, C."

Conference or Workshop Item

Duckworth, E., Feener, E., Yea, C. et al. (3 more authors) (2022) Rapid Plasma Kallikrein Inhibition Following Oral KVD900 is Associated With Early Symptom Relief in Patients With Hereditary Angioedema. In: 2022 AAAAI Annual Meeting, 25-28 Feb 2022, Phoenix, Arizona.

Bernstein, J., Li, H., Yea, C. et al. (5 more authors) (2021) A022 on-demand oral treatment with kvd900 for hae attacks achieves rapid exposure and improves patient outcomes. In: 2021 Annual Scientific MeetingAmerican College of Allergy, Asthma & Immunology, 04-08 Nov 2021, New Orleans, Louisiana.

Yea, C., Audhya, P., Williams, P. et al. (1 more author) (2021) P052 relationship between PGI-C scale and other pros in KVD900 trial in HAE. In: 2021 Annual Scientific MeetingAmerican College of Allergy, Asthma & Immunology, 04-08 Nov 2021, New Orleans, Louisiana.

Proceedings Paper

Smith, M., Iverson, M., Hansen, E. et al. (2 more authors) (2023) A Comparative Bioavailability of Sebetralstat Following Administration of Orally Disintegrating Tablets and Film-Coated Tablets in Healthy Volunteers. In: Journal of Allergy and Clinical Immunology. 2023 AAAAI Annual Meeting, 24-27 Feb 2023, San Antonio, USA. Elsevier , AB140-AB140.

Bernstein, J., Riedl, M., Lumry, W. et al. (3 more authors) (2023) Treatment with Sebetralstat Reduces the Cumulative Symptom Severity of Hereditary Angioedema Attacks in a Phase 2 Trial. In: Journal of Allergy and Clinical Immunology. 2023 AAAAI Annual Meeting, 24 Feb 2023 - 27 Feb 2024, San Antonio, USA. Elsevier , AB130-AB130.

Longhurst, H.J., Smith, M.D., Yea, C. et al. (1 more author) (2022) SEBETRALSTAT EFFECTIVENESS IN THE TREATMENT OF HEREDITARY ANGIOEDEMA ATTACKS RATED MILD OR MODERATE AT BASELINE IN THE PHASE 2 TRIAL. In: INTERNAL MEDICINE JOURNAL. 32nd Annual Conference of the Australasian Society of Clinical Immunology and Allergy (ASCIA), 30 Aug - 02 Sep 2022, Melbourne, Australia. , p. 29.